Sugi Predict

Sugi Predict / Compounds / SCHEMBL335730

SCHEMBL335730

SCHEMBL335730

Cc1ncc(C=O)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A3 P47895 2/20 0.41
▸ ALDH1A1 P00352 7/20 0.39
▸ ALDH3A1 P30838 1/20 0.39
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ AOX1 Q06278 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ TRIM24 O15164 1/20 0.36
▸ TRIM33 Q9UPN9 1/20 0.36
▸ PTGER4 P35408 1/20 0.34
▸ CYP2A6 P11509 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ESR1 P03372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38662682 1.00 ALDH1A3 (0.41) ALDH1A3ALDH1A1ALDH3A1LMNAKDM4E
SCHEMBL30590409 0.78 ALDH1A1 (0.39) ALDH1A3ALDH1A1LMNAKDM4EKMT2A
SCHEMBL335598 0.78 ALDH1A1 (0.39) ALDH1A3ALDH1A1LMNAKDM4EKMT2A
SCHEMBL336038 0.75 ALDH1A1 (0.43) ALDH1A3ALDH1A1ALDH3A1LMNAKDM4E
SCHEMBL7981808 0.75 ALDH1A3 (0.37) ALDH1A3ALDH1A1ALDH3A1LMNAMAPK1
SCHEMBL31672969 0.75 ALDH1A1 (0.44) ALDH1A1LMNAKDM4EKMT2AMEN1
SCHEMBL29954683 0.75 ALDH1A1 (0.43) ALDH1A3ALDH1A1ALDH3A1LMNAKDM4E
SCHEMBL335669 0.75 ALDH1A1 (0.37) ALDH1A1LMNAKDM4EKMT2AMEN1
SCHEMBL7101112 0.75 ALDH1A1 (0.39) ALDH1A3ALDH1A1LMNAMAPK1MAPT
SCHEMBL29955433 0.75 ALDH1A1 (0.37) ALDH1A1LMNAKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 — — US disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 — — WO disclosed
US-20210300900-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 — — US disclosed
EP-3810595-A1 OGA INHIBITOR COMPOUNDS Janssen Pharmaceutica NV (BE) 2021-04-28 — — EP disclosed
CN-112334462-A OGA inhibitor compounds 詹森药业有限公司 2021-02-05 — — CN disclosed
WO-2019243531-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 — — WO disclosed
EP-2300476-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS Glaxo Group Limited (GB) 2011-03-30 — — EP disclosed
EP-2238135-A1 NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS Glaxo Group Limited (GB) 2010-10-13 — — EP disclosed
WO-2010081874-A1 NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2010-07-22 — — WO disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 — — US disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 — — US disclosed
US-20090306089-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 — — US disclosed
WO-2009141398-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-11-26 — — WO disclosed
WO-2009141398-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-11-26 — — WO disclosed
WO-2009090222-A1 NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-07-23 — — WO disclosed
WO-2009090222-A1 NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLQ, POLB, POLK ALDH1A3 2325/4885ALDH1A1 1052/4885ALDH3A1 560/4885
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 ALDH1A3 2296/4885ALDH1A1 840/4885ALDH3A1 337/4885
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses POLA1, CTDSP1, SUB1 ALDH1A3 2098/4885ALDH1A1 589/4885ALDH3A1 289/4885
US-20090306089-A1 COMPOUNDS SDHA, NQO1, SDHB ALDH1A3 1456/4885ALDH1A1 612/4885ALDH3A1 715/4885
US-20210300900-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN ALDH1A3 4063/4885ALDH1A1 3839/4885ALDH3A1 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.